Surgical menopause women Bone loss Surgical menopause Bone turnover markers Serum CTX Serum P1NP
Conditions
Interventions
Surgical menopause women who indicated and received hormone treatment,Surgical menopause women who not received hormone treatment
Treatment,Treatment
Hormone treatment group,No hormone treatment group
Sponsors
Ratchadapiseksompotch Fund
Ratchadapiseksompotch Fund
Eligibility
Sex/Gender
Female
Age
40 Years to 55 Years
Inclusion criteria
Inclusion criteria: Premenopausal women age 40-55 years Planned surgical menopause due to benign conditions
Exclusion criteria
Exclusion criteria: Secondary amenorrhea Receiving hormone therapy Receiving glucocorticoid more than 3 months Underlying disease affected bone turnover markers eg DM, Hyperparathyroidism
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of bone turnover markers, between hormone treatment and no treatment 12 weeks Serum CTX | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation between age, FSH level at surgical menopause and change of bone turnovers markers 12 weeks Serum FSH, Serum CTX, Serum P1NP | — |
Countries
Thailand
Contacts
Public ContactJarika Vatrasresth
Faculty of medicine, Chulalongkorn University
Outcome results
None listed